Zosano Pharma Corporation (ZSAN) saw its loss widen to $7.75 million, or $0.46 a share for the quarter ended Dec. 31, 2016. In the previous year period, the company reported a loss of $7.65 million, or $0.64 a share.
The company has not recorded any revenues for the current quarter as well as previous year period.
Operating loss for the quarter was $7.45 million, compared with an operating loss of $7.18 million in the previous year period.
"The past year was an important period of progress for the Company as we initiated and in the fourth quarter completed ZOTRIP, our pivotal efficacy trial in migraine," commented Konstantinos Alataris, PhD, president and chief executive officer of Zosano Pharma. "Subsequent to the fiscal year end, we announced positive results from the ZOTRIP trial, which not only advances our lead migraine program towards FDA approval but also further validates the effectiveness of our technology platform. If approved, M207 could be an important new therapeutic option for migraine patients."
Disclaimer: Please note that this is an auto-generated article. IRIS does not guarantee the accuracy, adequacy or completeness of any information and is not responsible for any errors or omissions or for the results obtained from the use of such information. IRIS especially states that it has no financial liability whatsoever to any user on account of the use of information provided on its website. For queries contact: [email protected]
